(Q38114478)

29 August 2017

title

Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option (English)

1 reference

recurrent endometrial cancer

29 August 2017

main subject

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

1

1 reference

29 August 2017

author name string

Claudia Sergiampietri

series ordinal

2

1 reference

29 August 2017

Ilaria Guiggi

series ordinal

3

1 reference

29 August 2017

publication date

14 June 2013

1 reference

Gynecological Endocrinology

29 August 2017

published in

1 reference

29 August 2017

volume

29

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

811-816

1 reference

Endometrial carcinoma: pathology and genetics.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

The evolving role of adjuvant therapy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Molecule-targeted agents in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Clinical predictors of bevacizumab-associated gastrointestinal perforation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

FGFR2 as a molecular target in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2013.801446

10.3109/09513590.2013.801446

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference